About Qiming
Qiming is a venture capital firm founded in 2006. It is primarily based out of Cambridge, United States. As of Sep 2026, Qiming is an active investor, having invested in 38 companies, with 2 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series A round of Altis Labs Overall, Qiming portfolio has seen 1 unicorn, 6 IPOs and 11 acquisitions including key companies like Jasper Therapeutics, Korro Bio and HilleVax. A lot of funds co-invest with Qiming, with names like VenBio sharing a substantial percentage of its portfolio. Qiming has team of 9 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 5 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months
Qiming's List of Top Investments
Qiming has a portfolio of 38 companies, one of which is a Unicorn. Their most notable investments are in Twine Health and Auron Therapeutics.Their portfolio spans across United States, Canada, Ireland and 1 more locations. They have invested in Life Sciences, HealthTech, Enterprise Applications and 4 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by Qiming:
1. Boulder Care
Provider of a telehealth-based addiction treatment services, offering whole-person care and unconditional support to individuals struggling with substance use disorders, including opioid and alcohol addiction.
Key facts about Boulder Care
- Founded Year: 2017
- Location: Portland (United States)
- Stage: Series C
- Total Funding till date: $85M
- Employee Count: 218 as on Sep 30, 2026
- Investors: Advance Venture Partners, First Round Capital and 13 Others
- Latest Funding Round: Grant (prize money), Aug 14, 2025, $*****
- Highlight: Editors' Pick
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells. It offers Briquilimab a targeted anti c-Kit monoclonal antibody to deplete mast cells and diseased stem cells for chronic urticaria and lower to intermediate risk myelodysplastic syndromes.
Key facts about Jasper Therapeutics
- Founded Year: 2018
- Location: Redwood City (United States)
- Stage: Public
- Total Funding till date: $50M
- Employee Count: 39 as on Sep 30, 2026
- Investors: Abingworth, Qiming and 7 Others
- Latest Funding Round: Post IPO, Jul 21, 2026, $*****
- Highlight: Public
3. Korro Bio
Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases. The company's OPERA platform uses chemically modified oligonucleotides, including CHORD designs, to promote high-specificity RNA editing without the risks of DNA editing. This approach redirects endogenous cellular machinery to target specific RNA bases, enabling tunable modulation of protein function.
Key facts about Korro Bio
- Founded Year: 2018
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $4M
- Employee Count: 78 as on Sep 30, 2026
- Investors: Atlas Venture, Fidelity Investments and 15 Others
- Latest Funding Round: Post IPO, Apr 18, 2024, $*****
- Highlight: Public
Developer of cancer therapeutics. The company has developed in vivo cellular immunotherapy platform that uses gene therapy to target and attack cancer cells. The company's products include VivoVec that acts through the body’s lymphatic system, to produce cancer-fighting VivoCAR T cells. The company's proprietary RACR/CAR system is used to enhance the activity of VivoCAR T cells. The company's other product includes TumorTag which is used to tag targeted tumor cells/stromal elements.
Key facts about Umoja Biopharma
- Founded Year: 2019
- Location: Seattle (United States)
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $363M
- Employee Count: 254 as on Sep 30, 2026
- Investors: RTW Investments, Temasek and 15 Others
- Latest Funding Round: Series C, Jan 14, 2025, $*****
- Highlight: Editors' Pick
5. HilleVax
Developer of a vaccine for norovirus infection. The lead candidate HIL-214 is a norovirus bivalent GI.1/GII.4 virus-like particle vaccine indicated for active immunization for the prevention of acute gastroenteritis caused by norovirus.
Key facts about HilleVax
- Founded Year: 2021
- Location: Boston (United States)
- Stage: Public
- Total Funding till date: $135M
- Employee Count: 62 as on Dec 31, 2022
- Investors: Perceptive Advisors, Frazier Life Sciences and 12 Others
- Latest Funding Round: Series D, Sep 08, 2021, $*****
- Highlight: Public
Qiming's Year-on-Year Investment Trends
Qiming has invested in 38 companies over the last 9 years, with an average of 2 new investments annually in the last 5 years. In 2025, it made 3 investments, while as of Sep 2026, it has made 2 investments in this year. Its most recent first time investment was in Altis Labs and most recent follow-on round was in Rhino.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 0 | 2 |
2025 | 2 | 1 | 3 |
2024 | 1 | 2 | 3 |
2023 | 2 | 0 | 2 |
2022 | 3 | 3 | 6 |
2021 | 3 | 2 | 5 |
2020 | 5 | 3 | 8 |
2019 | 5 | 2 | 7 |
2018 | 4 | 0 | 4 |
2017 | 5 | 0 | 5 |
Qiming's Investments by Stage
Qiming has made 12 investments in Series A stage with an average round size of $50.2M, 8 investments in Series B stage with an average round size of $66.4M and 4 investments in Seed stage with an average round size of $20.7M.Stage of entry | No. of Investments |
|---|---|
Series A | 12 |
Series B | 8 |
Seed | 4 |
Series C | 4 |
Series D | 2 |
Others | 2 |
Note: We have considered here, only first round of investments
Qiming's Investments by Sector
Qiming has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, Consumer and High Tech. Notably, it has invested in 36 Tech companies, 32 Enterprise (B2B) companies, 8 Software companies and at least 5 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 24 |
HealthTech | 9 |
Enterprise Applications | 6 |
Consumer | 4 |
High Tech | 3 |
Others | 9 |
Note: We have considered here, only first round of investments
Qiming's Investments by Geography
Qiming has made most investments in United States (28), followed by Canada where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 28 |
Canada | 2 |
Ireland | 1 |
Switzerland | 1 |
Note: We have considered here, only first round of investments
Qiming's recent investments
Qiming has made 2 investments in 2026 so far - Altis Labs and Windward Bio.Here are the most recent investments by Qiming:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 21, 2026 | Canada | Series A | 7680 | ||
May 04, 2026 | Switzerland | Series B | 3029 | [+11] | |
Jul 07, 2025 | United States | Series A | 1511 | [+4] | |
Jun 03, 2025 | United States | Seed | 6547 | [+2] | |
May 09, 2025 | United States | Series A | 9563 | [+8] |
Unicorns in Qiming's Portfolio
Qiming has 1 unicorn in its portfolio - LetsGetChecked. The most recent unicorn in their portfolio is LetsGetChecked which became a unicorn in 2021, 3 years after Qiming first invested in it.Here is a list of unicorns in Qiming's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
59 | Online platform to order at home diagnostic tests for all health conditions | 2013 | Dublin | Series D | fhee{sz |
IPOs and Publicly Listed companies in Qiming's Portfolio
6 of Qiming's portfolio companies have become public. Satellos Bioscience got listed on the Toronto Stock Exchange (TSX), in Feb 2024 and HilleVax got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $538M.Here are Qiming's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 15, 2024 | - | - | 8215 | |
Apr 29, 2022 | Sep 08, 2021 | Series D | 4142 | |
Jun 25, 2021 | Jul 21, 2020 | Series A | 3797 | |
May 07, 2021 | Apr 18, 2019 | Series A | 5698 | |
Jan 10, 2020 | Dec 06, 2019 | Series A | 2483 |
_1555914700798.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Acquired companies in Qiming's Portfolio
11 companies from Qiming's portfolio have been acquired. The most recent acquisition was Candid Therapeutics in May 2026 by UCB for $*****.Here are Qiming's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 03, 2026 | Sep 09, 2024 | Series D | 3481 | |
Mar 30, 2026 | Jul 21, 2017 | Series B | 8154 | |
Jan 07, 2026 | Mar 09, 2021 | Series B | 3567 | |
Sep 09, 2025 | - | - | 3616 | |
Jan 07, 2025 | Jun 12, 2017 | Series C | 7137 |
Team profile of Qiming
Qiming has a team of 9 members including 4 Partners and 2 Principals located in United States. Qiming's team sits on the board of 1 company.Here is a list of all team members in Qiming:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | ||
Partner | Bellevue | - | ||
Partner | Cambridge | - | ||
Partner | Los Angeles | - | ||
Principal | Boston | - | - | |
Principal | Cambridge | - | - |
Co-investors of Qiming
Over the past 9 years, 248 investors have co-invested in Qiming's portfolio companies. This includes funds and angels.
- Invested before Qiming: Versant Ventures, Orbimed and 60 others have invested in rounds before Qiming. There are 2 companies where Versant Ventures has invested before Qiming and 2 companies where Orbimed has invested before Qiming.
- Top Co-investors of Qiming: 107 investors entered a company along with Qiming. These include investors like VenBio (5 companies).
- Invested after Qiming: A total of 79 investors have invested in Qiming's portfolio after their investments. Top Investors include Janus Henderson Investors (4 companies), Qiming Venture Partners (3 companies) and Invus (2 companies).
Recent News related to Qiming
•
Altis Labs Raises US$25 Million Series A Funding Led by OrbiMed and Qiming Venture Partners USAFinancial Post•Sep 17, 2026•Altis Labs, Orbimed, Altis, Qiming
•
Tenpoint Therapeutics Raises $235M Through Series B and Credit FacilityFinSMEs•Jan 29, 2026•Tenpoint Therapeutics, Hercules Capital, Hillhouse, Sofinnova Partners and 7 others
•
Dualitas Therapeutics Raises $65M for Bispecific Antibody PipelinePharmaceutical Business Review•Sep 17, 2025•Qiming, SV Health Investors
•
Renasant Bio, developing ADPKD drugs, raises $55M in seed fundingBioPharmaDive•Jul 10, 2025•Renasant Bank, Novartis, 5AM Ventures, Atlas Venture and 2 others
•
Rhino Federated Computing Secures $15M in Series A FundingFinSMEs•May 22, 2025•Rhino, Arkin, AlleyCorp, Qiming and 3 others
•
Umoja secures $100m to advance CAR-T cell therapy pipelinePharmaceutical Technology•Jan 15, 2025•Umoja Biopharma, Double Point Ventures, DCVC, ARK Investment Management and 3 others
•
Soda Health closes oversubscribed $50M Series B led by General Catalyst to scale its SmartBakersfield•Dec 03, 2024•Soda Health, General Catalyst, SVB, Qiming and 2 others
•
Candid Therapeutics Debuts With $370m Capital Raise To Clinically Evaluate Potentially Transformative Autoimmune TherapiesBusiness Wire•Sep 09, 2024•Candid, Venrock, Fairmont, TCG Crossover and 16 others
•
Tenaya Therapeutics Secures $50 Million in Share SaleTipRanks•Feb 09, 2024•Tenaya Therapeutics, Leerink Partners, Cowen, Jasper Therapeutics and 20 others
•
Tenpoint Therapeutics Launches With $70 Million in Funding for Cell Therapy to Reverse Vision LossVision Monday•Jul 14, 2023•Tenpoint Therapeutics, British Patient Capital, Sofinnova Partners, F-Prime Capital and 3 others
